Online first
Wytyczne / stanowisko ekspertów
Opublikowany online: 2024-09-04
Wyświetlenia strony
352
Wyświetlenia/pobrania artykułu
34
Errata została opublikowana:
#1
Rekomendacje Zespołu Ekspertów i Polskiej Grupy Raka Płuca dotyczące stosowania chemioterapii w skojarzeniu z ozymertynibem w leczeniu chorych na niedrobnokomórkowego raka płuca z wariantami patogennymi genu EGFR
1
, 1, 2, 3, 4, 5, 6, 7, 3, 1, 8, 9, 10, 6, 1
, 1, 2, 3, 4, 5, 6, 7, 3, 1, 8, 9, 10, 6, 1
Streszczenie
Brak
Referencje
- Houston KA, Mitchell KA, King J, et al. Histologic Lung Cancer Incidence Rates and Trends Vary by Race/Ethnicity and Residential County. J Thorac Oncol. 2018; 13(4): 497–509.
- Nicholson AG, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer staging project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eight edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016; 11: 300–311.
- Postmus PE, Kerr KM, Oudkerk M, et al. ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4): iv1–iv21.
- Planchard D, Popat S, Kerr K, et al. ESMO Guidelines Committee. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Suppl 4): iv192–iv237.
- Lindeman N, Cagle P, Aisner D, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. J Thorac Oncol. 2018; 13(3): 323–358.
- Nicholson AG, Tsao MS, Beasley MB, et al. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. J Thorac Oncol. 2022; 17(3): 362–387.
- WHO Classification of Tumours Editorial Board. Thoracic Tumours. WHO classification of tumours series, 5th ed.; vol. 5. International Agency for Research on Cancer, Lyon 2021.
- Yatabe Y, Dacic S, Borczuk AC, et al. Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. J Thorac Oncol. 2019; 14(3): 377–407.
- Sholl LM, Cooper WA, Kerr KM, et al. IASLC Atlas of Molecular Testing for Targeted Therapy in Lung Cancer. IASLC Office, Denver 2023.
- Langfort R, Szołkowska M. Ocena ekspresji białka PD-L1 w kwalifikacji do leczenia chorych z niedrobnokomórkowym rakiem płuca. Pol J Pathol. 2024; 7(1): 8–12.
- Tsao MS, Hirsch FR, Yatabe Y. IASLC Atlas of ALK and ROS1 testing in lung cancer. Editorial Rx Press, North Fort Myers, FL 2016.
- Tan AC, Tan DSW. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. J Clin Oncol. 2022; 40(6): 611–625.
- Tsubata Y, Tanino R, Isobe T. Current Therapeutic Strategies and Prospects for EGFR Mutation-Positive Lung Cancer Based on the Mechanisms Underlying Drug Resistance. Cells. 2021; 10(11).
- Pretelli G, Spagnolo CC, Ciappina G, et al. Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical Need. Int J Mol Sci. 2023; 24(10).
- Palacín-Aliana I, García-Romero N, Asensi-Puig A, et al. Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR. Biomedicines. 2021; 9(8).
- Passiglia F, Bironzo P, Bertaglia V, et al. Optimizing the clinical management of -mutant advanced non-small cell lung cancer: a literature review. Transl Lung Cancer Res. 2022; 11(5): 935–949.
- Ramalingam S, Vansteenkiste J, Planchard D, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020; 382(1): 41–50.
- Planchard D, Jänne P, Cheng Y, et al. Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC. N Engl J Med. 2023; 389(21): 1935–1948.
- Jänne P, Planchard D, Kobayashi K, et al. CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor–Mutated Advanced Non–Small-Cell Lung Cancer. J Clin Oncol. 2024; 42(7): 808–820.
- Connor Wells J, Mullin MM, Ho C, et al. Outcomes of patients with advanced epithelial growth factor receptor mutant lung cancer treated with first-line osimertinib who would not have met the eligibility criteria for the FLAURA clinical trial. Lung Cancer. 2024; 190: 107529.
- Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26(21): 3543–3551.
- Dingemans AMC, Hendriks LEL, Berghmans T, et al. Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report. J Thorac Oncol. 2019; 14(12): 2109–2119.
- Gomez DR, Tang C, Zhang J, et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol. 2019; 37(18): 1558–1565.
- Tsai CJ, Yang JT, Shaverdian N, et al. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (consolidative use of radiotherapy to block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study. Lancet. 2024; 403(10422): 171–182.
- M.D. Anderson Cancer Center. Randomized Phase II Trial of Osimertinib With or Without Local Consolidation Therapy (LCT) for Patients With EGFR-Mutant Metastatic NSCLC (NORTHSTAR) [Internet]. clinicaltrials.gov; 2022 Sep [cited 2022 Nov 3]. Report No.: NCT03410043. https://clinicaltrials.gov/ct2/show/NCT03410043.
- Khan TM, Verbus EA, Gandhi S, et al. Osimertinib, Surgery, and Radiation Therapy in Treating Patients with Stage IIIB or IV Non-Small Cell Lung Cancer with EGFR Mutations (NORTHSTAR). Ann Surg Oncol. 2022; 29(8): 4688–4689.
- Amini A, Rusthoven CG. Ablative Radiation Therapy for Oligometastatic EGFR-Mutated Non-small Cell Lung Cancer: Who, Why, When, and How? Int J Radiat Oncol Biol Phys. 2023; 116(3): 481.
- Bindels BJJ, Mercier C, Gal R, et al. Stereotactic Body and Conventional Radiotherapy for Painful Bone Metastases: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2024; 7(2): e2355409.
- Thomas NJ, Myall NJ, Sun F, et al. Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation. J Thorac Oncol. 2022; 17(1): 116–129.
- Fong CH, Meti N, Kruser T, et al. Recommended first-line management of asymptomatic brain metastases from EGFR mutant and ALK positive non-small cell lung cancer varies significantly according to specialty: an international survey of clinical practice. J Thorac Dis. 2023; 15(8): 4367–4378.
- Kroeze SGC, Pavic M, Stellamans K, et al. Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium. Lancet Oncol. 2023; 24(3): e121–e132.
